The efficacy of calcitriol therapy in the management of bone loss and fractures: A qualitative review

Osteoporosis International

Volumn 21, Issue 7, 2010, Pages 1133-1149

  Peppone, L J ^a,d   Hebl, S ^b   Purnell, J Q ^a   Reid, M E ^c   Rosier, R N ^d   Mustian, K M ^a   Palesh, O G ^a   Huston, A J ^d   Ling, M N ^a   Morrow, G R ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Bone biomarkers; Calcitriol; Clinical trials; Primary osteoporosis; Review; Secondary osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; OSTEOCALCIN; PLACEBO; ROCATROL; UNCLASSIFIED DRUG; VITAMIN D; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; BONE REMODELING; BONE TURNOVER; CALCIUM INTAKE; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG EFFICACY; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; MENOPAUSE; MONOTHERAPY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUALITY OF LIFE; REVIEW; SECONDARY OSTEOPOROSIS; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; VITAMIN INTAKE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; TREATMENT OUTCOME;

EID: 79954491341     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1136-2     Document Type: Review

References (124)

1. United States. Public Health Service. Office of the Surgeon General. (2004) Bone health and osteoporosis a report of the Surgeon General. In. U.S. Dept. of Health and Human Services, Public Health Service, Rockville, MD, Washington, D.C.
2. Liu H, Paige NM, Goldzweig CL, Wong E, Zhou A, Suttorp MJ, Munjas B, Orwoll E, Shekelle P (2008) Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med 148:685-701
3. Looker AC, Bauer DC, Chesnut CH 3rd, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH (2000) Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 11:467-480
4. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Watts NB (1999) Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 2:323-342
5. Garnero P, Delmas PD (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:1046-1053
6. Seeman E (2003) Invited review: pathogenesis of osteoporosis. J Appl Physiol 95:2142-2151
7. Dennison E, Mohamed MA, Cooper C (2006) Epidemiology of osteoporosis. Rheum Dis Clin North Am 32:617-629
8. Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302
9. Stein E, Shane E (2003) Secondary osteoporosis. Endocrinol Metab Clin North Am 32:115-134 vii
10. Saag KG (2003) Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 32:135-157 vii
11. van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
12. Riggs BL, Khosla S, Melton LJ 3rd (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13: 763-773
13. Cancer survivorship - United States, 1971-2001. MMWR Morb Mortal Wkly Rep (2004) 53:526-529
14. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM (2005) Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 23: 5814-5830
15. Ganz PA (2005) A teachable moment for oncologists: cancer survivors, 10 million strong and growing! J Clin Oncol 23:5458-5460
16. Greep NC, Giuliano AE, Hansen NM, Taketani T, Wang HJ, Singer FR (2003) The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 114:653-659
17. Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18: 1570-1593
18. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656-3661
19. Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311
20. Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9:R28
21. Roach M 3rd (1999) Current status of androgen suppression and radiotherapy for patients with prostate cancer. J Steroid Biochem Mol Biol 69:239-245
22. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, Fasolis G, Fontana D, Rossetti SR, Angeli A (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361-2367 discussion 2367
23. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC (2007) Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8:119-127
24. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M (2001) Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166:1724-1728
25. Andersen SJ (2007) Osteoporosis in the older woman. Clin Obstet Gynecol 50:752-766
26. Gass M, Dawson-Hughes B (2006) Preventing osteoporosis-related fractures: an overview. Am J Med 119:S3-S11
27. Riggs BL, Melton LJ 3rd (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17:505S-511S
28. Ray NF, Chan JK, Thamer M, Melton LJ 3rd (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24-35
29. Richmond J, Aharonoff GB, Zuckerman JD, Koval KJ (2003) Mortality risk after hip fracture. J Orthop Trauma 17:53-56
30. Melton LJ 3rd (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18: 1139-1141
31. Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151:2026-2032
32. Orwoll ES (1999) Osteoporosis in men: the effects of gender on skeletal health. Academic, San Diego
33. United States. Congress. Office of Technology Assessment (1994) Hip fracture outcomes in people age fifty and over. U.S. G.P.O., Washington, D.C, The Office
34. Ross PD (1997) Clinical consequences of vertebral fractures. Am J Med 103:30S-42S discussion 42 S-43 S
35. Magaziner J, Hawkes W, Hebel JR, Zimmerman SI, Fox KM, Dolan M, Felsenthal G, Kenzora J (2000) Recovery from hip fracture in eight areas of function. J Gerontol 55: M498-M507
36. Tosteson AN, Hammond CS (2002) Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmaco Econ 20:289-303
37. Papaioannou A, Watts NB, Kendler DL, Yuen CK, Adachi JD, Ferko N (2002) Diagnosis and management of vertebral fractures in elderly adults. Am J Med 113:220-228
38. O'Donnell S, Moher D, Thomas K, Hanley DA, Cranney A (2008) Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 26:531-542
39. Lau KH, Baylink DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65:295-306
40. Frolik CA, Deluca HF (1971) 1,25-dihydroxycholecalciferol: the metabolite of vitamin D responsible for increased intestinal calcium transport. Arch Biochem Biophys 147:143-147
41. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E (1999) The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:311-316
42. Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301-310
43. Bischoff HA, Stahelin HB, Tyndall A, Theiler R (2000) Relationship between muscle strength and vitamin D metabolites: are there therapeutic possibilities in the elderly? Z Rheumatol 59(Suppl 1):39-41
44. Bischoff HA, Stahelin HB, Urscheler N, Ehrsam R, Vonthein R, Perrig-Chiello P, Tyndall A, Theiler R (1999) Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 80:54-58
45. Xia WB, Zhang ZL, Wang HF, Meng XW, Zhang Y, Zhu GY, Xing XP, Liu JL, Wang LH, Jiang Y, Weng SF, Xu T, Hu YY, Yu W, Tian JP (2009) The efficacy and safety of calcitriol and/or Caltrate D in elderly Chinese women with low bone mass. Acta Pharmacol Sin 30:372-378
46. Tinetti ME, Speechley M, Ginter SF (1988) Risk factors for falls among elderly persons living in the community. N Engl J Med 319:1701-1707
47. Evans JG (1988) Falls and fractures. Age Ageing 17:361-364
48. Dukas L, Staehelin HB, Schacht E, Bischoff HA (2005) Better functional mobility in community-dwelling elderly is related to D-hormone serum levels and to daily calcium intake. J Nutr Health Aging 9:347-351
49. Faulkner KA, Cauley JA, Zmuda JM, Landsittel DP, Newman AB, Studenski SA, Redfern MS, Ensrud KE, Fink HA, Lane NE, Nevitt MC (2006) Higher 1,25-dihydroxyvitamin D3 concentrations associated with lower fall rates in older community-dwelling women. Osteoporos Int 17:1318-1328
50. Moreland JD, Richardson JA, Goldsmith CH, Clase CM (2004) Muscle weakness and falls in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 52:1121-1129
51. Muir SW, Berg K, Chesworth B, Klar N, Speechley M (2009) Quantifying the magnitude of risk for balance impairment on falls in community-dwelling older adults: a systematic review and meta-analysis. J Clin Epidemiol. doi:10.1016/j.jclinepi.2009.06.010
52. Gallagher JC (2004) The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 89-90:497-501
53. Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618-3628
54. Richy F, Dukas L, Schacht E (2008) Differential effects of d-hormone analogs and native vitamin d on the risk of falls: a comparative meta-analysis. Calcif Tissue Int 82:102-107
55. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL (2005) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev CD000227.
56. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY (2005) Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 76:176-186
57. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D (2009) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2:CD000227
58. Jones G, Hogan DB, Yendt E, Hanley DA (1996) Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis. CMAJ 155:955-961
59. Nuti R, Bonucci E, Brancaccio D, Gallagher JC, Gennari C, Mazzuoli G, Passeri M, Sambrook P (2000) The role of calcitriol in the treatment of osteoporosis. Calcif Tissue Int 66: 239-240
60. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589-602
61. Dechant KL, Goa KL (1994) Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis. Drugs Aging 5:300-317
62. Eastell R, Hannon RA (2008) Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 67:157-162
63. Garnero P (2008) Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 12:157-170
64. Pagani F, Francucci CM, Moro L (2005) Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest 28:8-13
65. Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH (1988) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84:401-408
66. Caniggia A, Nuti R, Galli M, Lore F, Turchetti V, Righi GA (1986) Effect of a long-term treatment with 1,25-dihydroxyvitamin D3 on osteocalcin in postmenopausal osteoporosis. Calcif Tissue Int 38:328-332
67. Caniggia A, Nuti R, Lore F, Martini G, Turchetti V, Righi G (1990) Long-term treatment with calcitriol in postmenopausal osteoporosis. Metabolism 39:43-49
68. Gallagher JC, Jerpbak CM, Jee WS, Johnson KA, DeLuca HF, Riggs BL (1982) 1,25-Dihydroxyvitamin D3: short- and longterm effects on bone and calcium metabolism in patients with postmenopausal osteoporosis. Proc Natl Acad Sci U S A 79:3325-3329
69. Gram J, Junker P, Nielsen HK, Bollerslev J (1996) Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males. Bone 18:539-544
70. Inanir A, Ozoran K, Tutkak H, Mermerci B (2004) The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis. J Int Med Res 32:570-582
71. Lambrinoudaki I, Chan DT, Lau CS, Wong RW, Yeung SS, Kung AW (2000) Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J Rheumatol 27:1759-1765
72. Ott SM, Chesnut CH 3rd (1989) Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 110:267-274
73. Riggs BL, Nelson KI (1985) Effect of long term treatment with calcitriol on calcium absorption and mineral metabolism in postmenopausal osteoporosis. J Clin Endocrinol Metab 61:457-461
74. Sairanen S, Karkkainen M, Tahtela R, Laitinen K, Makela P, Lamberg-Allardt C, Valimaki MJ (2000) Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1,25-dihydroxyvitamin D (Calcitriol) for four years. Calcif Tissue Int 67:122-127
75. Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J (2000) Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15:1818-1824
76. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D (2004) Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767-776
77. Sirtori P, Sosio C, Resmini G, Rubinacci A (1996) Effect of short course of 1,25-dihydroxyvitamin D3 on biochemical markers of bone remodelling in postmenopausal women. Pharmacol Res 33:353-359
78. Stempfle HU, Werner C, Echtler S, Wehr U, Rambeck WA, Siebert U, Uberfuhr P, Angermann CE, Theisen K, Gartner R (1999) Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 68:523-530
79. Tjellesen L, Christiansen C, Rodbro P (1984) Effect of 1,25-dihydroxyvitamin D3 on biochemical indices of bone turnover in postmenopausal women. Acta Med Scand 215:411-415
80. Tsukamoto Y, Watanabe T, Nakagami T, Morishita K (2003) Effect of treatment with oral calcitriol on calcium metabolism and fasting serum 25(OH)- or 1,25(OH)2-vitamin D level in Japanese postmenopausal women. Endocr J 50:681-687
81. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
82. Ebeling PR, Wark JD, Yeung S, Poon C, Salehi N, Nicholson GC, Kotowicz MA (2001) Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. J Clin Endocrinol Metab 86:4098-4103
83. Arthur RS, Piraino B, Candib D, Cooperstein L, Chen T, West C, Puschett J (1990) Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women. Miner Electrolyte Metab 16:385-390
84. Dambacher MA, Kranich M, Schacht E, Neff M (1997) Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites? Calcif Tissue Int 60:115-118
85. Falch JA, Odegaard OR, Finnanger AM, Matheson I (1987) Postmenopausal osteoporosis: no effect of three years treatment with 1,25- dihydroxycholecalciferol. Acta Med Scand 221:199-204
86. Fujita T (1990) Studies of osteoporosis in Japan. Metabolism 39:39-42
87. Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113:649-655
88. Mirzaei S, Zajicek HK, Knoll P, Hahn M, Levi M, Kohn H, Pohl W (2003) Effect of rocaltrol on bone mass in patients with pulmonary disease treated with corticosteroids. J Asthma 40:251-255
89. Need AG, Nordin C, Horowitz M, Morris HA (1990) Calcium and calcitriol therapy in osteoporotic postmenopausal women with impaired calcium absorption. Metabolism 39:53-54
90. Tilyard M (1990) Low-dose calcitriol versus calcium in established postmenopausal osteoporosis. Metabolism 39:50-52
91. Diaz PR, Neira LC, Fischer SG, Teresa Torres MC, Milinarsky AT, Giadrosich VR, Arriagada MM, Arinoviche RS, Casanova DM (2008) Effect of 1,25(OH)2-vitamin D on bone mass in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 30:15-19
92. Caniggia A, Nuti R, Martini G, Frediani B, Giovani S, Valenti R, Silvestri G, Matarazzo M (1996) Efficacy and safety of long-term, open-label treatment with calcitriol in postmenopausal osteoporosis: a retrospective analysis. Curr Ther Res 57:857-868
93. Gallagher JC, Riggs BL, Recker RR, Goldgar D (1989) The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 191:287-292
94. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362
95. Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G (2007) Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc 55:752-757
96. Cosman F, Nieves J, Shen V, Lindsay R (1995) Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy. J Bone Miner Res 10:594-600
97. Eriksson SA, Lindgren JU (1993) Combined treatment with calcitonin and 1,25-dihydroxyvitamin D3 for osteoporosis in women. Calcif Tissue Int 53:26-28
98. Gram J, Junker P, Nielsen HK, Bollerslev J (1998) Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone 23:297-302
99. Gutteridge DH, Holzherr ML, Retallack RW, Price RI, Will RK, Dhaliwal SS, Faulkner DL, Stewart GO, Stuckey BG, Prince RL, Criddle RA, Drury PJ, Tran L, Bhagat CI, Kent GN, Jamrozik K (2003) A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density. Calcif Tissue Int 73:33-43
100. Rhee Y, Kang M, Min Y, Byun D, Chung Y, Ahn C, Baek K, Mok J, Kim D, Kim D, Kim H, Kim Y, Myoung S, Kim D, Lim SK (2006) Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos Int 17:1801-1807
101. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747-1752
102. Frediani B, Allegri A, Bisogno S, Marcolongo R (1998) Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: two years of continuous treatment. Clinical Drug Investigation 15:235
103. Gurlek A, Bayraktar M, Gedik O (1997) Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study. Calcif Tissue Int 61:39-43
104. Jensen GF, Christiansen C, Transbol I (1982) Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol (Oxf) 16:515-524
105. Malavolta N, Zanardi M, Veronesi M, Ripamonti C, Gnudi S (1999) Calcitriol and alendronate combination treatment in menopausal women with low bone mass. Int J Tissue React 21:51-59
106. Masud T, Mulcahy B, Thompson AV, Donnelly S, Keen RW, Doyle DV, Spector TD (1998) Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 57:346-349
107. Schacht E, Dukas L, Richy F (2007) Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. JMNI 7:174-184
108. Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW (2008) A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int 102:1601-1606
109. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW (2007) Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25:669-674
110. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21:123-128
111. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G (2007) Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int 100:775-779
112. Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM (2005) High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 174:888-892
113. Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, Schwartz J, Brattain MG, Hutson A, French R, Johnson CS (2007) A phase I pharmacokinetic and pharmaco-dynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 13:1216-1223
114. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL (2007) Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 59:581-587
115. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS (2006) Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 106:2136-2142
116. Beer TM (2005) ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 96:508-513
117. Beer TM, Garzotto M, Katovic NM (2004) High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol 27:535-541
118. Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL (2005) Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res 11:7794-7799
119. Beer TM, Munar M, Henner WD (2001) A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 91:2431-2439
120. Beer TM, Myrthue A, Garzotto M, O'Hara MF, Chin R, Lowe BA, Montalto MA, Corless CL, Henner WD (2004) Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 13:2225-2232
121. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD (2008) Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112:326-330
122. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL (2002) Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72:648-659
123. Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL (2005) Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation. Cancer Chemother Pharmacol 56:492-496
124. Moher D, Schulz KF, Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191-1194